Literature DB >> 27408395

Methimazole Induced Total Myeloid Aplasia with Delayed Recovery Despite Granulocyte Colony Stimulating Factor (G-CSF): Marrow Progenitor Recovery Kinetics.

Tania Sarker1, Bülent Özgönenel1, Manisha Gadgeel1, Steven Buck1, Amita Adhikari2, Yaddanapudi Ravindranath1.   

Abstract

An eighteen-year-old female with Graves thyrotoxicosis presented with methimazole-induced agranulocytosis and total myeloid aplasia. The bone marrow at presentation showed complete absence of myeloid precursors and striking plasmacytosis. 16 days later, myeloid precursors were still absent morphologically; however bone marrow flow cytometry and cell culture detected an improvement in myelogenesis, which was soon followed by clinical recovery of agranulocytosis. Neutrophil recovery was delayed until day 22 after cessation of methimazole despite G-CSF use, consistent with a direct toxic effect on committed myeloid cells. Our findings suggest that cell culture and flow cytometric evaluation of bone marrow myeloid progenitors can be used as a guide to anticipate neutrophil recovery.

Entities:  

Keywords:  Bone marrow cell culture; Flow cytometry; G-CSF; Methimazole; Total myeloid aplasia

Year:  2015        PMID: 27408395      PMCID: PMC4925526          DOI: 10.1007/s12288-015-0595-1

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  23 in total

Review 1.  Bone-marrow transplantation (second of two parts).

Authors:  E D Thomas; R Storb; R A Clift; A Fefer; L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-24       Impact factor: 91.245

2.  Immune-mediated agranulocytosis related to drugs and their metabolites: mode of sensitization and heterogeneity of antibodies.

Authors:  A Salama; B Schütz; V Kiefel; H Breithaupt; C Mueller-Eckhardt
Journal:  Br J Haematol       Date:  1989-06       Impact factor: 6.998

3.  Successful treatment of methimazole-induced severe aplastic anaemia in a diabetic patient with other co-morbidities.

Authors:  Cindy V Josol; Myrna Buenaluz-Sedurante; Mark Anthony Sandoval; Gerry Castillo
Journal:  BMJ Case Rep       Date:  2010-12-20

4.  Methimazole-induced agranulocytosis: growth inhibition of myeloid progenitor cells by the patient's serum.

Authors:  D Douer; Z Eisenstein
Journal:  Eur J Haematol       Date:  1988-01       Impact factor: 2.997

Review 5.  The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis.

Authors:  Danka J F Stuijver; Bregje van Zaane; Erica Romualdi; Dees P M Brandjes; Victor E A Gerdes; Alessandro Squizzato
Journal:  Thromb Haemost       Date:  2012-09-26       Impact factor: 5.249

Review 6.  Thyrotoxicosis and thyroid storm.

Authors:  Bindu Nayak; Kenneth Burman
Journal:  Endocrinol Metab Clin North Am       Date:  2006-12       Impact factor: 4.741

7.  Antithyroid drug-induced aplastic anemia.

Authors:  Dimitrios Thomas; Anestis Moisidis; Aristotelis Tsiakalos; Krystallenia Alexandraki; Vassiliki Syriou; Gregory Kaltsas
Journal:  Thyroid       Date:  2008-10       Impact factor: 6.568

8.  Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.

Authors:  Kazuna Takata; Sumihisa Kubota; Shuji Fukata; Takumi Kudo; Eijun Nishihara; Mitsuru Ito; Nobuyuki Amino; Akira Miyauchi
Journal:  Thyroid       Date:  2009-06       Impact factor: 6.568

9.  Granulocyte colony-stimulating factor treatment of antithyroid drug-induced granulocytopenia.

Authors:  J Tajiri; S Noguchi; S Okamura; M Morita; M Tamaru; N Murakami; Y Niho
Journal:  Arch Intern Med       Date:  1993-02-22

10.  Successful treatment of methimazole-induced severe aplastic anemia by granulocyte colony-stimulating factor, methylprednisolone, and cyclosporin.

Authors:  Munehiro Honda
Journal:  ISRN Endocrinol       Date:  2011-04-10
View more
  1 in total

Review 1.  Neuroprotection through G-CSF: recent advances and future viewpoints.

Authors:  Vikrant Rahi; Sumit Jamwal; Puneet Kumar
Journal:  Pharmacol Rep       Date:  2021-01-02       Impact factor: 3.024

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.